Startup profile · funding coverage
Anacalypsis Therapeutics funding, valuation and investors
Greek drug-discovery biotech that raised a €300,000 pre-seed round led by Metavallon VC to advance a Parkinson's disease program.
Keep track of Anacalypsis Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Pre-seed
€300K · September 21, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
pre seed · Athens, Greece
Investors in latest funding
Lead: Metavallon VC
Overview
Anacalypsis Therapeutics is developing treatments for Parkinson's disease and other neurodegenerative disorders. On September 21, 2026 Metavallon VC announced a €300,000 pre-seed investment through its Brain Gain Fund to advance lead candidate AT001 and the broader pipeline.
Why Anacalypsis Therapeutics is interesting
A first-of-its-kind local drug-discovery investment in Greece with primary investor disclosure.
Key facts
- Sep 21, 2026: €300K pre-seed led by Metavallon VC
Funding history (newest first)
Pre-seed
2026-09-21 €300K- Metavallon VC (lead)
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.